PNPLA3 and metabolic dysfunction-associated steatohepatitis: More specifically, a 50% reduction of PNPLA3 should be beneficial, because humans with one of two copies of PNPLA3 148M have an increased risk of NASH compared to non-carriers, with odds ratios of 2.35 and 5.05, respectively [6].